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Objectives: To test whether low molecular mass heparin (LMMH) is comparable tounfractionated heparin (UFH) as an 
anticoagulant during infrainguinal bypass urgery and to investigate laboratory evidence of hypercoagulation in patients 
undergoing infrainguinal bypass urgery. 
Materials and methods: Eighteen patients were randomised to receive ither UFH or LMMH (70 anti-Xa units/kg b.w.). 
Soluble fibrin, measured as fibrin monomers (FM) and fibrinopeptide A (FPA), were measured in blood from the femoral 
vein before, during and after release of the occluding clamps during surgery. In addition, fibrinogen prothrombin complex, 
thrombin-antithrombin complex, platelets and antithrombin were measured before surgery. Heparin levels (Anti Xa) were 
measured uring surgery. 
Results: Increased levels of fibrinogen, FPA, thrombin antithrombin complex and FM were recorded prior to surgery. 
During surgery no further increase was noted. The anti Xa levels were slightly higher in patients with LMMH than in 
patients receiving UFH. Levels of FM were significantly lower in patients receiving LMMH. No difference in FPA was 
noted. A positive correlation between fibrinogen and FPA and FM respectively was recorded. Four patients, two in each 
group, were reoperated for graft occlusion. One patient in the UFH group required reoperation because of bleeding. 
Conclusions: LMMH is comparable toUFH as an anticoagulant during infrainguinal bypass urgery. Variables reflecting 
hypercoagulability are elevated in this group of patients and are positively correlated to the fibrinogen level. High fibrinogen 
levels could thus be a risk for perioperative thrombosis. 
Introduction 
Many haemostatic variables are affected in patients 
with lower extremity ischaemia. 1 These may contrib- 
ute to a hypercoagulable state possibly caused by 
activation by atherosclerotic vessels. Ulcers and gan- 
grene in the ischaemic extremity may add to the 
hypercoagulability b causing inflammation as it has 
been shown that interleukin-1, a mediator of inflam- 
mation, induces procoagulant activity in endothelial 
cells. 2 Changes in the composition of blood also 
contribute to increased coagulability. Patients with 
atherosclerosis are often smokers, which is associated 
with an increased haematocrit and fibrinogen, which 
is also increased independently of smoking. 3 When 
vessels are clamped during surger)~ the blood 
becomes tagnant which further increases the risk of 
thrombosis. All these factors: vessel wall changes, 
tissue necrosis in the affected limb and changes in the 
composition and flow of blood contribute to the 
hypercoagulable state in patients with atherosclerosis, 
necessitating anticoagulation during vascular recon- 
structive surgery. 
Previously, we have shown that increased coagula- 
tion activity during infrainguinal vascular surgery is 
generated in the ischaemic limb, by demonstrating a 
difference between the levels of fibrinopeptide A
(FPA) in the femoral artery and vein of the affected 
limb. 4 FPA is a sensitive measure of ongoing coagula- 
tion since it is cleaved off from fibrinogen during 
fibrin formation. The increased coagulability, i.e. for- 
mation of FPA, could be prevented by heparin 
administration. Most surgeons advocate the use of 
heparin to prevent arterial thrombosis during clamp- 
ing. The dosage, however, varies considerably. 5 Until 
now, unfractionated heparin (UFH) has been used 
almost exclusively and it is not known whether a low 
molecular mass heparin (LMMH) can be used instead. 
LMMH has certain advantages, among other being a 
more refined preparation with improved antithrombo- 
tic properties and a lesser risk of bleeding. 6 
The purpose of the present study was two-fold: 
Firstly to investigate whether LMMH could be used as 
an anticoagulant during infrainguinal vascular sur- 
gery and secondly to examine whether laboratory 
evidence of increased coagulability in general, and 
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levels of fibrinogen in particular, are present in this 
group of patients. 
Materials and Methods 
Patients 
Eighteen patients cheduled for saphenous vein infra- 
inguinal bypass were randomised to receive either 
UFH (Heparin Pharmacia, Sweden) or LMMH (Frag- 
min Pharmacia, Sweden) in a dose of 70 anti Xa units/ 
kg i.v. during surgery. Eleven men and seven women 
were included in the stud)~ five men and four women 
in the UFH group and six men and three women in the 
LMMH group. The mean age was 77 years, 78 for 
patients receiving UFH and 76 for patients receiving 
LMMH. The preoperative ankle brachial index was 
0.21 + 0.2 range 0-0.54. The mean ABI was 0.19 in the 
UFH group and 0.22 in the LMMH group. Three 
patients were operated for claudication, (UFH = 1, 
LMMH = 2). Six patients were operated for rest pain 
(UFH = 2, LMMH = 4) and finally nine patients were 
operated for ulcers or gangrene (UFH = 6, LMMH = 3). 
Five were current and eight were previous smokers, 
three patients had never smoked. Thirteen patients 
received a femorodistal bypass (UFH = 6, LMMH = 7). 
Of the remaining five patients, three received a 
femoropopliteal bypass with the distal anastomosis 
below the knee (UFH = 1, LMMH = 2) and the remain- 
ing two, one in each group, had the distal anastomosis 
above the knee. Blood samples were obtained preop- 
eratively from an antecubital vein and perioperatively 
from the femoral vein of the leg that was operated 
upon. The study was approved by the local ethical 
committee. 
Methods 
Fibrinopeptide A (FPA), fibrin monomers (FM), 
thrombin-antithrombin complex (TAT), heparin, 
hematocrit and platelet count were measured inblood 
drawn from the femoral vein before clamping, during 
clamping and after release of the clamps on comple- 
tion of the vascular econstruction. These coagulation 
variables were also measured in peripheral blood 
preoperatively in addition to fibrinogen, activated 
partial thromboplastin time (APTT) and prothrombin 
complex (PK). During surgery the effect of dilution 
was corrected according to the haematocrit. 
FPA was measured with a radioimmunoassay 
according to Nossel et al., 7 as modified by Kockum 
and Frebelius. 8 Fibrin monomers were measured as 
soluble fibrin. 9 TAT was measured with an ELISA 
metlaod, w Heparin was measured as anti Xa activity 
according to Teien et al. ~1 In plasma samples from 
patients receiving LMMH, this was used as a standard 
and UFH was used as a standard when measuring 
heparin activity in samples from patients receiving 
UFH. Fibrinogen was measured with a clotting 
method. 12 Antithrombin III was measured as anti Xa 
activity. 1a APTT, PK, haematocrit and platelet count 
were measured with standard methods. Results are 
expressed as mean + 1 S.D. for clinical data and 
median + 95% confidence interval for laboratory data. 
Statistical analysis was by the Mann-Whitney U-Test. 
The null hypothesis was rejected if p < 0.5. 
Results 
All patients urvived the procedure. Four graft occlu- 
sions occurred postoperatively, two in the UFH group 
and two in the LMMH group. One of these, a patient 
who received LMMH, was successfully thrombecto- 
mised but the remaining three were reoccluded. One 
patient receiving UFH required reoperation for 
bleeding. 
Preoperatively the patients all had increased levels 
of fibrinogen, FPA, FM and TAT compared to normal 
values established at the laboratory, indicating a 
hypercoagulable state. The normal values, at least for 
fibrinogen and FPA, have been shown to be relatively 
independent of age. 14 There was, however, aconsider- 
able variation in all these parameters eflected in the 
wide confidence intervals (Table 1). No difference in 
fibrinogen levels between on smokers and previous 
or present smokers was seen in this small group. 
At surgery blood was drawn from the femoral vein 
before clamping, as late as possible before release of 
the proximal clamp, i.e. during maximal ischaemia 
Table 1. 
Test Normal Patient values 
values (median d 95% 
confidence interval) 
Fibrin monomers <15 21 
(mmol/1) 15.5-51.0 
Thrombin-antithrombin complex <4.0 7.6 
(~g/1) 5.0-42.0 
Fibrinopeptide A <2.0 33.0 
(nmol/1) 30.4-87.6 
Fibfinogen 2.1--4.2 4.9 
(g/l) 4.1-5.7 
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and after elease of the distal clamp. The time from the 
preclamp blood sampling to that taken during clamp- 
ing was 43 rain + 16, 39 + 12 in the UFH group and 
48 _+ 19 in the LMMH group. The time between the 
preclamp blood sampling and that obtained after 
release of the clamps was 128 min __. 37, 133 + 44 for the 
UFH and 123 + 28 in the LMMH group. 
The analysis of samples obtained from the femoral 
vein during clamping and after release of the clamps 
showed that the heparin level, measured as anti Xa 
activity, was higher in the LMMH group, both during 
clamping and at declamp (0.71 and 0.56 respectively). 
The corresponding values for the UFH group was 0.56 
and 0.28. The anti Xa activity of plasma was influ- 
enced by the time that had evolved since administra- 
tion of LMMH or UFH. This is illustrated in Fig. 1, 
where anti Xa activities obtained after release of the 
clamp are plotted against he time interval between 
administration of the anticoagulant and blood sam- 
pling. As shown by the figure there is a decreasing anti 
Xa activity in both groups but the level of anti Xa is 
higher in the LMMH group. 
FPA, TAT and FM were measured in blood samples 
obtained uring clamping, i.e. at maximal ischaemia 
and after release of the clamp. The wide confidence 
intervals noted preoperatively were considerably 
reduced. The only difference between the groups was 
a lower value for FM in the LMMH group, both 
during clamping and after elease of the clamps (Fig. 2 
a and b). The FM values were significantly lower in 
the group receiving LMMH compared to those receiv- 
ing UFH during clamping (p=0.026). In samples 
obtained after release of the clamps there was no 
significant difference (p = 0.09). 
When analysing the influence of fibrinogen upon 
levels of both FPA and FM, a strong positive correla- 
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Fig. 1. Anti Xa activity plotted against ime after administration of
LMMH or UFH. (C)) UFH; (X) LMMH. 
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tion was found. An example, obtained at release of the 
clamps, is shown in Fig. 3 a and b. 
Discussion 
Anticoagulation during bypass urgery is used mostly 
on empirical grounds, based on the concept hat the 
decreased blood flow caused by clamping of the 
arteries contributes to thrombosis. The fact that 
patients Undergoing vascular econstruction already 
have preoperative laboratory evidence of a hyper- 
coagulable state, as shown by increased levels of FPA, 
FM, TAT and fibrinogen, further supports the use of 
anticoagulants during vascular surgery. 
The hypercoagulability s at least partly caused by 
factors in the ischaemic leg since it has been shown 
that there is an arteriovenous difference in the 
operated leg for FPA. ~S In this study we only obtained 
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Fig. 2. Box plot representations of (a) Soluble fibrin measured as 
fibrin monomers during damping in patients receiving UFH and 
LMMH. The difference is significant (Mann-Whitney U-test, 
p = 0.03). Co) Soluble fibrin measured as fibrin monomers after 
release of the damps in patients receiving UFH and LMMH. The 
p-value for the difference is 0.09 (Mann-Whitney U-test). 
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samples from the femoral vein, since venous samples 
have been shown to adequately reflect increased 
coagulation generated in the ischaemic limb. 4 In the 
absence of heparinisation, there is a high incidence of 
thrombosed bypass grafts, 4and so most surgeons use 
intraoperative anticoagulants. In a recent report 97% 
of American surgeons and 89% of European surgeons 
reported use of systemic heparin during femoro- 
popliteal and femoroinfrapopliteal reconstructive sur- 
gery. 5 Most of them seem to use a fixed dose of 
heparin. In the present study this was avoided by 
giving 70 anti Xa units/kg body weight to the 
patients. Adjusted dosage of heparin has the theoret- 
ical advantage of avoiding overdose in patients with a 
low body weight. This may not only give rise to 
postoperative bleeding but also necessitate r versal of 
heparin with protamine which may be associated with 
severe side effects including thrombocytopenia, hypo- 
tension and pulmonary artery hypertensionJ 6'17 
LMMH has only been utilised as a perioperative 
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Fig. 3. (a) Fibrin monomers plotted against fibrinogen concentration 
in patients receiving UHF and LMMH after elease of the damps 
(r = 0.847, p< 0.0001). (lo) Fibrinopeptide A plotted against fibrino- 
gen concentration after elease of the damp, (r = 0.75, p = 0.0007). (©) 
UFH; (R) LMMH. 
anticoagulant in two previous tudies, both involving 
patients undergoing aortic reconstructive surgeryJ 8'19 
LMMH is a derivative of UFH and is characterised by 
shorter polysaccharide chain lengths, which mainly 
prevent coagulation by inhibiting factor Xa. The 
longer chains, which are only present in UFH, inhibit 
coagulation by enhancing complex formation of AT 
with thrombin. Thus, LMMH mainly inhibits the 
coagulation cascade at a level above thrombin forma- 
tion. It has been reported that the use of LMMH is 
associated with less risk of bleeding than UFH when 
comparing dosages of equal antithrombotic effect. 6A 
possible disadvantage with LMMH is that it cannot be 
completely reversed with protamine, 2°'21 but prota- 
mine should be avoided if possible because of its 
toxicityJ 6'17 The need for heparin reversal can be 
minimised by giving adjusted dosage of heparin 
instead of fixed doses. LMMH is probably excreted 
largely through the kidneys 22 and consequently an 
increased diuresis may improve the elimination of 
LMMH if bleeding occurs. 
In the present study the anti Xa activity was higher 
in patients given LMMH than in those given UFH. 
Similar findings have been obtained in healthy indi- 
viduals. 23 The elimination of i.v. UFH has been 
reported to be more rapid than that for LMMH. The 
elimination curves for LMMH are independent of 
dosage but the elimination of UFH is prolonged with 
increasing dosage, which makes comparisons difficult. 
There seemed to be no great difference in elimination 
rate between UFH and LMMH in the present study 
which is in agreement with an earlier report compar- 
ing LMMH and UFH in vascular surgery. In that 
study, however, the anti Xa activity was not greatly 
different in those given LMMH compared to those 
given UFH irrespective of the fact that LMMH was 
given in a slightly higher dosage calculated as anti Xa 
units. 19 In this context it should be pointed out that it 
is important o use the appropriate standard when 
constructing the standard curves, i.e. LMMH should 
be used when constructing the curves for anti Xa 
activity for the LMMH patients and UFH should be 
used for samples obtained from those receiving 
UFH. 
Previous studies examining the effect of LMMH in 
aortic surgery have concluded that it is equally 
effective ~9 or superior 18 to UFH. The latter study 
suggests that injection of the drug should be into the 
aorta in order to produce less systemic activity. ~4 The 
present study concludes that LMMH can be used 
equally well as UFH in infrainguinal bypass urgery. If 
anything, LMMH had a better effect based on the 
finding that FM levels were lower during clamping 
and at declamping in the LMMH group. A superior 
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antithrombotic effect achieved by LMMH was, how- 
ever, not reflected by FPA levels. FPA has a shorter 
half-life than FM and therefore short episodes of 
hypercoagulation may go undetected. FPA is also a 
more difficult test since its high sensitivity in detecting 
coagulation activity can result in sampling errors 
caused by activation of the blood against surfaces of 
the sample tubes. Clinically there was no difference 
between the two groups but detection of a possible 
difference in bleeding complications would require a 
much larger study. 
In conclusion, this study confirms that patients with 
arterial occlusive disease have laboratory signs indi- 
cating a hypercoagulable state. FPA, FM and TAT, 
variables reflecting thrombin formation or action were 
elevated preoperatively with wide confidence inter- 
vals. This was mostly due to a skewed distribution 
with some patients howing very high levels. During 
surgery the confidence intervals were approximately 
halved which indicates that administration of the 
anticoagulant prevented excessive coagulant activity. 
The fibrinogen level was likewise elevated and corre- 
lated with variables reflecting coagulant activity. If the 
coagulation cascade is triggered, increased levels of 
the substrate for the enzymatic action (fibrinogen) 
may make the condition more severe. It has previously 
been suggested that increased levels of fibrinogen 
contribute to thrombotic omplications in connection 
with surgery in this patient group. 4 Fibrinogen is 
reported to be an important risk factor for athero- 
sclerosis 25 and is associated with mortality and 
adverse vents in claudicants. 26It may be that it is also 
associated with a risk of thrombotic omplications 
perioperatively. 
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